Dennis Stearns, MS, CCIM

Experience

• 

  Mid Continent Controls

  Mar 1996 - Jun 2005

  Vice President / Engineering - CoFounder

  As a leader in the aviation industry for over 20 years, Mid Continent Controls understands the bond between pilot/owner and plane, and provides innovative solutions combined with cutting edge technology and electronics to meet any power, cabin, or in-flight entertainment challenge. We’re passionate about what we do, so we dig in deep to assess your individual and customer demographic requirements, analyze your pain points, then provide a cost-effective, feature-rich, customized solution to meet any size of VIP aircraft cabin.www.midcontinentcontrols.com Show less

• 

  Stearns Commercial, LLC

  Jun 2005 - now

  Principal

  CRE Investment (MF, MHP, Self-Storage, Mixed Use & Warehouse)

• 

  Stage I Diagnostics, Inc.

  Jan 2013 - Feb 2019

  Director

  Stage I Diagnostics is a diagnostic research company focused on the development of assays to detect and diagnose cancer at its earliest stage. Currently, our primary offerings are related to the diagnosis of prostate and the early detection of ovarian cancer. We are unique. Our tests are not merely current assays that are bundled and packaged as a novel assay, but rather, our tests were researched and developed through The University of Arkansas for Medical Sciences Bio-Ventures Program. We cloned, developed and patented our assays for use in many forms of cancer. Our tests provide significant insight for the physician regarding the actual tumor activity rather than simply reflecting tumor burden. Show less

• 

  Arkansas Building Authority

  Jan 2015 - Jan 2016

  Council Member
• 

  Broadband Development Group, LLC

  May 2015 - now

  Broadband Development Group (BDG) was formed to address pent up demand for high-performance, affordable broadband Internet access. We enter markets where new technology combined with innovative business models enable a compelling competitive advantage. Our initial focus is on broadband Internet access for residential and business subscribers in Multi-Tenant Units. We have designed a network architecture and business model to deliver broadband in this segment that is up to 600% faster than the fastest speed available in most markets, and which is typically 40% cheaper at every speed. Furthermore, we offer customers instant activation and no hassles - no waiting, no modem, and no contract. Services under our HyperLeap brand launched mid-2015. Show less

  • Investor

    Jan 2023 - now

  • Director

    May 2015 - Jan 2023
• 

  ZUNI Learning Tree

  Mar 2016 - now

  Angel Investor

  ZUNI Learning Tree is a cloud-based online platform with curated free and open source learning and teaching materials and resources for teachers, parents and students. ZUNI Learning Tree’s platform contains links to resources such as games, videos, lesson plans, STEM resources, technology how-to videos, art activities and more. The ZUNI Learning Tree platform is an equalizer for genders, races, bilingual, special education and socioeconomic groups to advance their skills and knowledge. We are a hub where students who are behind grade level in academic skills can access and find the tools they need to address their gaps; a hub where students who want to advance and explore beyond standard expectations can do so; a hub where girls will be inspired to enter into the science, math, engineering and technology (STEM) fields; a place where bilingual children and parents can access tools to teach and improve English language skills and knowledge. Because at ZUNI Learning Tree we know that lives, communities and dreams change with education. We are committed to making it easy to maintain a life-long love of learning for everyone. Show less

• 

  Navaux

  Feb 2019 - now

  Director

  We believe that detection of cancer at its earliest stages offer the patient and physician the best opportunity to effectively treat the disease with the fewest adverse side effects. Being able to determine that an aggressive cancer is in development before clinical symptoms arise will lead to longer survival and better quality of life for patients. In addition to the diagnostic potential of our biomarkers, they hold the real possibility of being targets for future therapies which could be more effective than current protocols while producing far fewer and less severe side effects. Show less